Form 8-K KERYX BIOPHARMACEUTICALS For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Roth Capital Remains Positive on Keryx (KERX) Following Q3 Results, Update
November 6, 2014 11:27 AM ESTRoth Capital affirmed Keryx Biopharma (Nasdaq: KERX) at Buy with a price target of $32 following Q3 results reported earlier Thursday. Keryx posted Q3 loss of $0.38 per share, while Roth was looking for a loss of just $0.24 per share.
Analyst Joseph Pantginis commented, The third quarter represented a successful period for KERX, with the approval of Ferric Citrate in September 2014 for the control of serum phosphorus... More
